Pharmaceutical promotion and GP prescription behaviour

Health Economics

Volumn 15, Issue 1, 2006, Pages 5-18

  Windmeijer, Frank ^a   de Laat, Eric ^b   Douven, Rudy ^b   Mot, Esther ^b  

^a INSTITUTE FOR FISCAL STUDIES   (United Kingdom)

^b CPB NETHERLANDS BUREAU FOR ECONOMIC POLICY ANALYSIS   (Netherlands)

Author keywords

Drug price elasticity; Panel data; Promotion expenditures

Indexed keywords

ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; GENERIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; NEW DRUG; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ALLERGY; ARTICLE; ASTHMA; DEPRESSION; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; FINANCIAL MANAGEMENT; GENERAL PRACTITIONER; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; LAW; MIGRAINE; NETHERLANDS; NONBIOLOGICAL MODEL; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; STATISTICAL ANALYSIS; STOMACH DISEASE; ULCER;

DRUG COSTS; DRUG INDUSTRY; DRUG UTILIZATION; DRUGS, GENERIC; EDUCATION, MEDICAL, CONTINUING; FAMILY PRACTICE; FEES, PHARMACEUTICAL; HUMANS; MARKETING; MODELS, ECONOMETRIC; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRESCRIPTIONS, DRUG; TRAINING SUPPORT;

EID: 31344476470     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1007     Document Type: Article

References (18)

1. OECD. OECD Health Data 2000. A comparative analysis of 29 countries 2000 (cd-rom).
2. Jacobzone S. Pharmaceutical policies in OECD countries: Reconciling social and industrial goals, Labour Market and Social Policy - Occasional Papers 40, OECD, Paris, 2000.
3. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG. Demand effects of recent changes in prescription drug promotion, Report prepared for the Kaiser Family Foundation, Menlo Park (CA), USA.
4. Scherer FM. The pharmaceutical industry. In: Handbook of Health Economics, vol. 1B. Culyer AJ, Newhouse JP (eds). Elsevier: Amsterdam, 2000.
5. Hurwitz MA, Caves RE. Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J Law Econ 1988; 31: 299-320.
6. Rizzo JA. Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. J Law Econ 1999; 42: 89-116.
7. Matraves C. Market structure, R&D and advertising in the pharmaceutical industry. J Ind Econ 1999; 47: 169-194.
8. Gönül FF, Carter F, Petrova E, Srinivasan K. Promotion of prescription drugs and its impact on physicians' choice behavior. J Marketing 2001; 65: 79-90.
9. De Laat E, Windmeijer F, Douven R. How does pharmaceutical marketing influence doctors' prescribing behaviour? CPB Netherlands Bureau for Economic Policy Analysis, the Hague, 2001.
10. Coscelli A. The importance of doctor's and patients preferences in the prescription decision. J Ind Econ 2000; 48: 349-369.
11. Public Citizen. R&D myths: the case against the drug industry's R&D 'scare card'. Public Citizen Congress Watch, Washington, DC, 2001.
12. Berndt ER. Pharmaceuticals in US health care: determinants of quality and price. J Econ Perspectives 2002; 16: 45-66.
13. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-142.
14. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-185.
15. GIP/CVZ. GIPeilingen 2000: Kengetallen farmaceutische hulp [Core statistics pharmaceutical care 2000], Genees- en hulpmiddelen informatie project (GIP)/College voor zorgverzekeringen, Diemen, July 2002.
16. Medische Promotie Index, IMS HEALTH Nederland b.v., the Hague.
17. Dorfman R, Steiner PO. Optimal advertising and optimal quality. Am Econ Rev 1954; 44: 826-836.
18. Azoulay P. Do pharmaceutical sales respond to scientific evidence? J Econ Manage Strategy 2002; 11: 551-594.